2010

  • Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs. Biogen Idec will make an initial payment of USD 32.5 million and up to USD 395 million in contingent payments.
  • Molecular Partners has been selected as a World Economic Forum Technology Pioneer 2011.
  • The Biotech Center Zurich becomes a member of the Technopark Alliance, and its name is changed to Bio-Technopark Schlieren-Zurich.

2009

  • Molecular Partners secures CHF 46 million in Series B financing.
  • US company Alcon acquires ESBATech AG for USD 150 million in cash and up to USD 439 million based upon achievement of future milestones. The rights to the technology and products for application outside of ophtalmology will be retained by the previous shareholders of ESBATech and spun off into a separate new company, Delenex Therapeutics AG.
  • Merger of biotop Life Science Incubator Schlieren and Biotech Center Zurich, and the setting up of a branch office.

2008

  • Series B financing round amounting to more than CHF 73 million by ESBATech AG.
  • CHF 150 million collaboration between Cytos Biotechnology AG and Pfizer Inc.